Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer

British Journal of Cancer

Volumn 98, Issue 4, 2008, Pages 742-748

  Kaira, K ^a   Oriuchi, N ^a   Imai, H ^a   Shimizu, K ^a   Yanagitani, N ^a   Sunaga, N ^a   Hisada, T ^a   Tanaka, S ^a   Ishizuka, T ^a   Kanai, Y ^b   Endou, H ^c   Nakajima, T ^a   Mori, M ^a  

^a GUNMA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYORIN UNIVERSITY   (Japan)

Author keywords

Amino acid transporter; Ki 67; LAT1; Nonsmall cell lung cancer; Prognostic factor

Indexed keywords

AMINO ACID TRANSPORTER; KI 67 ANTIGEN; PLATINUM DERIVATIVE; TEGAFUR;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CELL PROLIFERATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 39449101130     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604235     Document Type: Article

References (29)

1. Brundage MD, Davies D, Mackillop WJ (2002) Prognostic factors in non-small cell lung cancer: a decade of prognosis. Chest 122: 1037-1057
2. Buck AC, Schirrmeister HH, Guhlmann CA, Diederichs CG, Shen C, Buchmann I, Kotzerke J, Birk D, Mattfeldt T, Reske SN (2001) Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity? J Nucl Med 42: 721-725
3. Chairoungdua A, Segawa H, Kim JY, Miyamoto K, Haga H, Fukui Y, Mizoguchi K, Ito H, Takeda E, Endou H, Kanai Y (1999) Identification of an amino acid transporter associated with the cystinuria-related type II membrane glycoprotein. J Biol Chem 274: 28845-28848
4. Christensen HN (1990) Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev 70: 43-77
5. Clinical Practice Guidelines for the Treatment of Unresectable Non-Small Cell Lung Cancer (1997) Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15: 2996- 3018
6. Fuchs BC, Bode BP (2006) Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 15: 254-266
7. Inoue T, Koyama K, Oriuchi N, Alyafei S, Yuan Z, Suzuki H, Takeuchi K, Tomaru Y, Tomiyoshi K, Aoki J, Endo K (2001) Detection of malignant tumors: whole-body PET with fluorine 18 α-methyl tyrosine vs FDG-preliminary study. Radiology 220: 54-62
8. Kaira K, Oriuchi N, Otani Y, Shimizu K, Tanaka S, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Dobashi K, Kanai Y, Endou H, Nakajima T, Endo K, Mori M (2007a) Fluorine-18-α-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: A Clinicopathological Study. Clin Cancer Res 13: 6369-6378
9. 18F-fluorodeoxyglucose in sarcoidosis patients. Chest 131: 1019-1027
10. Kanai Y, Endou H (2001) Heterodimeric amino acid transporters: molecular biology and pathological and pharmacological relevance. Curr Drug Metab 2: 339-354
11. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H (1998) Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 273: 23629- 23632
12. Kim CH, Park KJ, Park JR, Kanai Y, Endou H, Park JC, Kim do K (2006) The RNA interference of amino acid transporter LAT1 inhibits the growth of KB human oral cancer cells. Anticancer Res 26: 2943-2948
13. Kim DK, Kanai Y, Choi HW, Tangtrongsup S, Chairoungdua A, Babu E, Tachampa K, Anzai N, Iribe Y, Endou H (2002) Characterization of the system L amino acid transporter in T24 human bladder carcinoma cells. Biochim Biophys Acta 1565: 112-122
14. Kobayashi H, Ishii Y, Takayama T (2005) Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol 90: 233-238
15. Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP, Lafitte JJ, Sculier JP (2004) Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 91: 2018-2025
16. Matsuo H, Tsukada S, Nakata T, Chairoungdua A, Kim DK, Cha SH, Inatomi J, Yorifuji H, Fukuda J, Endou H, Kanai Y (2000) Expression of a system L neutral amino acid transporter at the blood-brain barrier. Neuroreport 11: 3507-3511
17. McGivan JD, Pastor-Anglada M (1994) Regulatory and molecular aspects of mammalian amino acid transport. Biochem J 299: 321 -334
18. Mountain CF (1997) Revision in the International System for staging lung cancer. Chest 11: 1710-1717
19. Nakanishi K, Matsuo H, Kanai Y, Endou H, Hiroi S, Tominaga S, Mukai M, Ikeda E, Ozeki Y, Aida S, Kawai T (2006) LAT1 expression in normal lung and in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Virchows Arch 448: 142-150
20. Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, Shima K, Matsuo H, Kanai Y, Endou H (2006) L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 119: 484-492
21. Ohkame H, Masuda H, Ishii Y, Kanai Y (2001) Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models. J Surg Oncol 78: 265-271; discussion 271-272
22. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Chevalier TL, Soria JC (2006) DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. New Engl J Med 355: 983-991
23. Oriuchi N, Higuchi T, Ishikita T, Miyakubo M, Hanaoka H, Iida Y, Endo K (2006) Present role and future prospect of positron emission tomography in clinical oncology. Cancer Sci 97: 1291-1297
24. Oxender DL, Christensen HN (1962) Evidence for two types of mediation of neutral amino acid transport in Ehrlich cells. Nature 197: 765-767
25. Shottenfeld D (1996) Epidemiology of Lung Cancer. Philadelphia, PA: Lippincott-Raven
26. Tamai S, Masuda H, Ishii Y, Suzuki S, Kanai Y, Endou H (2001) Expression of L-type amino acid transporter 1 in a rat model of liver metastasis: positive correlation with tumor size. Cancer Detect Prev 25: 439-445
27. Tomiyoshi K, Amed K, Muhammad S, Higuchi T, Inoue T, Endo K, Yang D (1997) Synthesis of new fluorine-18 labeled amino acid radiopharmaceutical: L-F-alpha-methyl tyrosine using separation and purification system. Nucl Med Commun 18: 169- 175
28. Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E, Anders MW, Endou H (2002) Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): Insights into the mechanisms of substrate recognition. Mol Pharmacol 61: 729-737
29. Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, Cha SH, Matsuo H, Fukushima J, Fukasawa Y, Tani Y, Taketani Y, Uchino H, Kim JY, Inatomi J, Okayasu I, Miyamoto K, Takeda E, Goya T, Endou H (2001) Human L-type amino acid transporter 1 (LAT 1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta 1514: 291-302